<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925547</url>
  </required_header>
  <id_info>
    <org_study_id>0315679-HS3</org_study_id>
    <nct_id>NCT01925547</nct_id>
  </id_info>
  <brief_title>Micellar Curcumin and Metabolic Syndrome Biomarkers</brief_title>
  <official_title>Effect of Micellar Curcumin on Inflammation and Lipid Metabolism Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of micellar curcumin on inflammation
      and lipid metabolism markers in subjects at risk for the metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum CRP in mg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma curcumin concentrations</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Concentrations (in nmol/L) of curcumin and curcumin conjugates in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum activity of ALT in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Fasting blood glucose in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma tumor necrosis factor alpha</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Plasma concentrations of TNFα in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum concentrations of uric acid in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma albumin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Plasma concentrations of albumin in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum total cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum triacylglycerols in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum HDL cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum LDL cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum activity of AST in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma glutamyl transferase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum activity of gamma-GT in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum activity of ALP in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum concentrations of bilirubin in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukine 6</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Plasma concentrations of IL-6 in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum concentrations of insulin in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Body weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Diastolic blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Serum concentrations of creatinine in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>At baseline and 6 weeks</time_frame>
    <description>Systolic blood pressure in mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Metabolic Syndrome, Protection Against</condition>
  <arm_group>
    <arm_group_label>Micellar curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Micellar curcumin</intervention_name>
    <description>80 mg micellar curcumin (oral) three times a day for six weeks</description>
    <arm_group_label>Micellar curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Total cholesterol &gt; 5.2 mmol/L

          -  LDL cholesterol &gt; 3.4 mmol/L

          -  Triglyceride &gt; 2.26 mmol/L

          -  CRP &gt; 2 mg/L

        Exclusion criteria:

          -  Intake of drugs or dietary supplements

          -  Pregnant women and breastfeeding mothers

          -  Smokers

          -  Previous illnesses such as heart attack, cancer or dementia

          -  Addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biological Chemistry and Nutrition, University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Kocher A, Bohnert L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016 Jul;60(7):1555-63. doi: 10.1002/mnfr.201501034. Epub 2016 May 23.</citation>
    <PMID>26909743</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hohenheim</investigator_affiliation>
    <investigator_full_name>Jan Frank</investigator_full_name>
    <investigator_title>Professor, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

